In Brief: Rep. Waxman
Executive Summary
Rep. Waxman: AmFAR's legislative representative and former Senate Aging Committee staffer Paul Kim to join Rep. Henry Waxman's (D-Calif.) personal staff Feb. 3. Kim will be in charge of FDA, NIH and other public health issues. He joined the American Foundation for AIDS Research in summer of 1996 after working for Sen. Pryor (D-Ark.) for two years. Kim also has experience with FDA and industry ("The Pink Sheet," Sept. 19, 1994, T&G-9)...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth